🚨 THE U.S. JUST FAST-TRACKED A KETAMINE PAINKILLER FOR THE BATTLEFIELD A drug better known for anesthesia and its controversial off-label use is suddenly at the center of a major U.S. military medical decision. The U.S. Department of Health and Human Services and the Department of Defense have opened an emergency pathway for Wafermine, a fast-dissolving ketamine wafer developed by Singapore-based iX Biopharma. The move follows a determination by Defense Secretary Pete Hegseth that U.S. forces face a heightened risk of chemical, biological, radiological or nuclear attacks. Under the emergency declaration, HHS Secretary Robert F. Kennedy Jr. authorized the use of certain medical countermeasures for moderate-to-severe acute pain caused by such encounters. The goal is to give troops a pain-relief option that can be used quickly when traditional medical support may be far away. Ketamine has been used for decades as an anesthetic, but it has also attracted growing attention as a powerful painkiller that works differently from traditional opioids. On a battlefield, where severe injuries can happen far from a hospital, a small wafer that dissolves quickly could potentially provide pain relief without requiring an injection. The development of Wafermine has also received major U.S. military backing, including a reported $41 million sole-source Department of Defense contract. But there is another side to the story. Emergency pathways exist for situations where waiting for the normal regulatory process could put lives at risk. At the same time, bypassing the usual approval route raises questions about how much clinical evidence should be required before a drug is widely deployed. Ketamine already has a complicated history of medical use, off-label treatment and regulatory scrutiny. So this is more than a story about a new painkiller. It is a glimpse into how medicine can change when the battlefield becomes the testing ground for new ways to save lives — and how quickly the rules can change when governments believe an emergency is approaching. Source: Fiore, K. (2026). Health, Defense Secretaries Pave Way for Ketamine Drug. MedPage Today.